Standard Versus Intensity-Modulated Pelvic Radiation Therapy in Treating Patients With Endometrial or Cervical Cancer

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Basic Trial Information

PhaseTypeStatusAgeSponsorProtocol IDs
Phase IIIBiomarker/Laboratory analysis, Supportive care, TreatmentActive18 and overNCI, OtherRTOG 1203
CDR0000738944, NCI-2012-02001, NCT01672892

Trial Description

Summary

RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.

PURPOSE: This randomized phase III trial is studying two different methods of radiation and their side effects and comparing how well they work in treating endometrial and cervical cancer after surgery.

Further Study Information

OBJECTIVES:

Primary

  • To determine if pelvic intensity-modulated radiation therapy (IMRT) reduces acute gastrointestinal toxicity in the 5th week (after 23-25 fractions) of pelvic radiation as measured with the expanded prostate cancer index composite (EPIC) instrument.

Secondary

  • To determine if grade 2+ gastrointestinal toxicity (Common Terminology Criteria for Adverse Events version 4.0 [CTCAE v. 4.0]) is reduced with IMRT compared to conventional whole-pelvis radiation therapy (WPRT).
  • To determine if grade 2+ hematologic toxicity (CTCAE v. 4.0) is reduced with IMRT compared to conventional WPRT.
  • To determine if urinary toxicity is reduced with IMRT using the EPIC urinary domain.
  • To validate EPIC bowel and urinary domains in women undergoing either IMRT pelvic radiation treatment or four-field pelvic radiation treatment for endometrial or cervical cancer.
  • To assess the impact of pelvic IMRT on quality of life using the Functional Assessment of Cancer Therapy-General (FACT-G) with cervix subscale.
  • To determine if there is any difference in local-regional control, disease-free survival, and overall survival between patients treated with IMRT as compared to conventional WPRT.
  • To perform a health-utilities analysis to measure the financial impact of pelvic IMRT via the EQ-5D instrument.
  • To identify molecular predictors of radiation toxicity and novel circulating cancer biomarkers.

OUTLINE: This is a multicenter study. Patients are stratified according to type of cancer (endometrial vs cervical), chemotherapy (none vs 5 courses of weekly cisplatin at 40 mg/m²), and radiation dose (45 Gy vs 50.4 Gy). Patients are randomized to 1 of 2 treatment arms.

  • Arm I: Patients undergo standard (3-dimensional) radiation therapy 5 days a week for up to 5-6 weeks.
  • Arm II: Patients undergo intensity-modulated radiation therapy (IMRT) 5 days a week for up to 5-6 weeks.

Some patients receive cisplatin IV over 1 hour on day 1. Treatment continues weekly for 5 weeks, concurrently with radiation therapy, in the absence of unacceptable toxicity or disease progression.

Tissue and blood samples may be collected for biomarker and correlative analysis.

Quality of life may be assessed by questionnaires (including the Expanded Prostate Cancer Index Composite [EPIC], the Functional Assessment of Cancer Therapy-General [FACT-G, Version 4], the EQ-5D, and the Common Toxicity Criteria Adverse Events - Patient-Reported Outcome [PRO-CTCAE]) instruments at baseline and periodically during and after study therapy.

After completion of study therapy, patients are followed every 6 months for the first 2 years and then annually for 5 years.

Eligibility Criteria

DISEASE CHARACTERISTICS:

  • Pathologically proven diagnosis of endometrial or cervical cancer
  • Patients must have undergone a hysterectomy (total abdominal hysterectomy, vaginal hysterectomy or radical hysterectomy, or total laparoscopic hysterectomy) for carcinoma of the cervix or endometrium within 49 days prior to registration
  • Performance of a bilateral salpingo-oophorectomy will be at the treating surgeon's discretion
  • No positive or close (< 3 mm) resection margins
  • Appropriate stage for protocol entry, including no distant metastases, based upon the following minimum diagnostic workup:
  • History/physical examination within 45 days prior to registration
  • Computed tomography (CT), magnetic resonance imaging (MRI), or positron emission tomography (PET)-CT including the abdomen and pelvis should be performed for initial radiological staging (performed pre- or post-surgery within 90 days prior to registration)
  • Imaging performed postoperatively should show no evidence of residual disease
  • Any evidence of malignancy identified on preoperative imaging should have been completely resected surgically prior to protocol treatment
  • Chest x-ray or chest CT must be performed within 90 days prior to registration (unless a PET-CT has been performed)
  • Endometrial cancer:
  • Patients with the following histologic features are eligible for pelvic radiation therapy without weekly cisplatin:
  • Less than 50% myometrial invasion, grade 3 adenocarcinoma without uterine serous carcinoma (USC), or clear cell histology
  • At least 50% myometrial invasion, grade 1-2 adenocarcinoma without USC, or clear cell histology
  • Patients with the following histologic features may be treated with pelvic radiation with or without weekly cisplatin (the decision to add weekly cisplatin for these patients is at the treating physician's discretion):
  • At least 50% myometrial invasion, grade 3 including USC and clear cell carcinoma
  • International Federation of Gynecology and Obstetrics (FIGO) 2009 stage II endometrial cancer of any grade including USC and clear cell carcinoma
  • FIGO 2009 stage IIIC1 (pelvic lymph node positive only, para-aortic nodes negative if removed) including USC and clear cell carcinoma. NOTE: If para-aortic nodes are not removed, CT abdomen or PET must demonstrate no evidence of lymphadenopathy.
  • Cervical cancer:
  • Patients with the following pathology findings may be treated with pelvic radiation with or without weekly cisplatin at the treating physician's discretion:
  • Patients with intermediate-risk features including two of the following histologic findings after radical hysterectomy: 1/3 or more stromal invasion, lymph-vascular space invasion or large clinical tumor diameter (> 4 cm)
  • Patients with cervical cancer treated with a simple hysterectomy with negative margins
  • Patients with any of the following criteria following radical hysterectomy are eligible for this study and must receive weekly cisplatin:
  • Positive resected pelvic nodes and para-aortic nodes negative if removed. NOTE: If para-aortic nodes are not removed, CT abdomen or PET CT must demonstrate no evidence of lymphadenopathy.
  • Microscopic parametrial invasion with negative margins
  • No patients with para-aortic nodal disease or who require extended-field radiotherapy beyond the pelvis
  • No patients with histology consisting of endometrial stromal sarcoma, leiomyosarcoma, malignant mixed mullerian tumor (MMMT), or carcinosarcoma
  • No evidence of metastatic disease outside of the pelvis

PATIENT CHARACTERISTICS:

  • Zubrod performance status 0-2
  • Absolute neutrophil count (ANC) ≥ 1,500 cells/mm³
  • Platelets ≥ 100,000 cells/mm³
  • Hemoglobin (Hgb) ≥ 8.0 g/dL (the use of transfusion or other intervention to achieve Hgb ≥ 8.0 g/dL is acceptable)
  • For patients receiving chemotherapy:
  • Within 14 days prior to registration, serum creatinine ≤ 1.5 mg/dL AND calculated creatinine clearance ≥ 50 mL/min
  • Aspartate aminotransferase (AST) ≤ 2 times upper limit of normal (ULN)
  • Bilirubin ≤ 2 times ULN
  • Alkaline phosphatase, magnesium, blood urea nitrogen (BUN), and electrolytes must be obtained and recorded
  • Fertile patients must use effective contraception
  • Not pregnant and/or breastfeeding
  • Willing and able to complete the bowel and urinary domains of the expanded prostate cancer index composite (EPIC) instrument prior to registration
  • No patients who exceed the weight/size limits of the treatment table or CT scanner
  • No mental status changes or bladder control problems that make the patient unable to comply with bladder-filling instructions
  • No prior invasive malignancy (except non-melanomatous skin cancer) unless disease-free for a minimum of 3 years
  • No patients with active inflammatory bowel disease
  • No severe, active co-morbidity, defined as follows:
  • Unstable angina and/or congestive heart failure requiring hospitalization within the last 6 months
  • Transmural myocardial infarction within the last 6 months
  • Acute bacterial or fungal infection requiring intravenous antibiotics at the time of registration
  • Other major medical illness that requires hospitalization or precludes study therapy at the time of registration
  • Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects (however, laboratory test coagulation parameters are not required for entry into this protocol)
  • Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition (however, human immunodeficiency virus [HIV] testing is not required for entry into this protocol)

PRIOR CONCURRENT THERAPY:

  • See Disease Characteristics
  • No prior radiation therapy to the pelvis
  • No prior treatment with platinum-based chemotherapy
  • Patients may NOT receive amifostine or other protective reagents

Trial Contact Information

Trial Lead Organizations/Sponsors

Radiation Therapy Oncology Group

  • National Cancer Institute
  • NRG Oncology
Ann Klopp, Principal Investigator

Trial Sites

U.S.A.

Arizona
Phoenix

Arizona Oncology - Deer Valley Center

David G. Brachman
Ph: 800-360-6371

Scottsdale

Arizona Oncology Services Foundation

David G. Brachman
Ph: 800-360-6371

California
Los Angeles

USC/Norris Comprehensive Cancer Center and Hospital

Suisui Song
Ph: 323-865-0451

Oakland

Kaiser Permanente-Oakland

Samantha A Seaward
Ph: 626-564-3455

Paradise

Feather River Hospital Cancer Center

Sam Mazj
Ph: 530-876-7995
Email: haleew@ah.org

Pomona

Robert and Beverly Lewis Family Cancer Care Center at Pomona Valley Hospital Medical Center

Yallapragada S. Rao
Ph: 909-865-9555

Rancho Cardova

Kaiser Permanente Medical Center - Rancho Cordova

Samantha A Seaward
Ph: 626-564-3455

Rohnert Park

Rohnert Park Cancer Center

Samantha A Seaward
Ph: 626-564-3455

Roseville

The Permanente Medical Group-Roseville Radiation Oncology

Samantha A Seaward
Ph: 626-564-3455

Sacramento

South Sacramento Cancer Center

Samantha A Seaward
Ph: 626-564-3455

University of California Davis Cancer Center

Jyoti S Mayadev
Ph: 916-734-3089

Santa Clara

Kaiser Permanente Medical Center - Santa Clara Homestead Campus

Samantha A Seaward
Ph: 626-564-3455

South San Francisco

Kaiser Permanente Cancer Treatment Center

Samantha A Seaward
Ph: 626-564-3455

Colorado
Aurora

University of Colorado Cancer Center at UC Health Sciences Center

Christine M Fisher
Ph: 720-848-0650

Colorado Springs

Penrose Cancer Center at Penrose Hospital

Keren Sturtz
Ph: 888-785-6789

Denver

Porter Adventist Hospital

Keren Sturtz
Ph: 888-785-6789

Englewood

Swedish Medical Center

Keren Sturtz
Ph: 888-785-6789

Littleton

Rocky Mountain Cancer Centers - Littleton

Keren Sturtz
Ph: 888-785-6789

Longmont

Hope Cancer Care Center at Longmont United Hospital

Keren Sturtz
Ph: 888-785-6789

Loveland

McKee Medical Center

Keren Sturtz
Ph: 888-785-6789

Delaware
Newark

Helen F. Graham Cancer Center at Christiana Hospital

Adam Raben
Ph: 302-733-6227

Rehoboth Beach

Beebe Health Campus

Adam Raben
Ph: 302-733-6227

District of Columbia
Washington

Washington Cancer Institute at Washington Hospital Center

Adedamola (Mola) B Omogbehin
Ph: 202-877-8839

Florida
Miami

Jackson Memorial Hospital

Lorraine Portelance
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

University of Miami Sylvester Comprehensive Cancer Center - Miami

Lorraine Portelance
Ph: 866-574-5124
Email: Sylvester@emergingmed.com

Georgia
Atlanta

Georgia Cancer Center for Excellence at Grady Memorial Hospital

Joseph W Shelton
Ph: 404-489-9164

Northside Hospital Cancer Center

Sahar E Rosenbaum
Ph: 404-303-3355

Piedmont Hospital

Adam W Nowlan
Ph: 404-425-7943
Email: ORS@piedmont.org

Winship Cancer Institute of Emory University

Joseph W Shelton
Ph: 404-489-9164

Joseph W Shelton
Ph: 404-489-9164

Augusta

Medical College of Georgia Cancer Center

Sharad Anant Ghamande
Ph: 706-721-1663
Email: cancer@georgiahealth.edu

Cumming

Northside Hospital-Forsyth

Sahar E Rosenbaum
Ph: 404-303-3355

Savannah

Nancy N. and J. C. Lewis Cancer and Research Pavilion at St. Joseph's/Candler

John A Pablo
Ph: 800-622-6877

Hawaii
Ewa Beach

Leeward Radiation Oncology

Paul A. DeMare
Ph: 808-545-8548

Honolulu

Cancer Research Center of Hawaii

Paul A. DeMare
Ph: 808-545-8548

Hawaii Medical Center - East

Paul A. DeMare
Ph: 808-545-8548

Queen's Cancer Institute at Queen's Medical Center

Paul A. DeMare
Ph: 808-545-8548

Idaho
Boise

Saint Alphonsus Cancer Care Center at Saint Alphonsus Regional Medical Center

Samir Narayan
Ph: 734-712-4673

Illinois
Chicago

Creticos Cancer Center at Advocate Illinois Masonic Medical Center

Paige L Dorn
Ph: 630-352-5300

John H. Stroger, Jr. Hospital of Cook County

Anupama Thakrar
Ph: 312-864-6000

Robert H. Lurie Comprehensive Cancer Center at Northwestern University

Eric D Donnelly
Ph: 312-695-1301
Email: cancer@northwestern.edu

University of Illinois Cancer Center

Andrew Howard
Ph: 312-355-3046

Harvey

Ingalls Cancer Care Center at Ingalls Memorial Hospital

Sulochana D Yalavarthi
Ph: 708-915-4673
Email: clinicaltrials@ingalls.org

Indiana
Anderson

Saint John's Health System

Maria J Valente
Ph: 904-538-3667

Fort Wayne

Radiation Oncology Associates Southwest

Brian K Chang
Ph: 260-373-8888
Email: parkviewresearch@parkview.com

Iowa
Ames

McFarland Clinic, PC

Joseph James Merchant
Ph: 515-239-2621

Des Moines

John Stoddard Cancer Center at Iowa Methodist Medical Center

Robert J Behrens
Ph: 515-282-2921

Kansas
Kansas City

Kansas Masonic Cancer Research Institute at the University of Kansas Medical Center

Parvesh Kumar
Ph: 913-588-4709

Salina

Tammy Walker Cancer Center at Salina Regional Health Center

Parvesh Kumar
Ph: 913-588-4709

Louisiana
Baton Rouge

Mary Bird Perkins Cancer Center - Baton Rouge

Augusto C Ochoa
Ph: 504-568-2428
Email: emede1@lsuhsc.edu

Maryland
Baltimore

Alvin and Lois Lapidus Cancer Institute at Sinai Hospital

Jeanette A. F. Linder
Ph: 410-601-6120
Email: pridgely@lifebridgehealth.org

Greater Baltimore Medical Center Cancer Center

Geoffrey A Neuner
Ph: 443-849-3706

Salisbury

Peninsula Regional Medical Center

Matthew L Snyder
Ph: 866-922-6237

Massachusetts
Boston

Boston University Cancer Research Center

Lisa A. Kachnic
Ph: 617-638-8265

Dana-Farber/Brigham and Women's Cancer Center

Akila Viswanathan
Ph: 617-724-5200

Dana-Farber/Harvard Cancer Center at Dana-Farber Cancer Institute

Akila Viswanathan
Ph: 617-724-5200

Milford

Dana-Farber/Brigham and Women's Cancer Center at Milford Regional Medical Center

Akila Viswanathan
Ph: 617-724-5200

South Weymouth

Dana-Farber/Brigham and Women's Cancer Center at South Shore

Akila Viswanathan
Ph: 617-724-5200

Michigan
Ann Arbor

Saint Joseph Mercy Cancer Center

Samir Narayan
Ph: 734-712-4673

Detroit

Van Elslander Cancer Center at St. John Hospital and Medical Center

Samir Narayan
Ph: 734-712-4673

Grand Rapids

Butterworth Hospital at Spectrum Health

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Lacks Cancer Center at Saint Mary's Health Care

Gilbert D Padula
Ph: 616-685-5225
Email: connie.szczepanek@grcop.org

Warren

St. John Macomb Hospital

Samir Narayan
Ph: 734-712-4673

Minnesota
Bemidji

MeritCare Bemidji

Preston D. Steen
Ph: 701-234-6161

Saint Paul

United Hospital

Paul Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Waconia

Ridgeview Medical Center

Paul Sperduto
Ph: 952-993-1517
Email: MMCCOP@parknicollet.com

Missouri
Saint Louis

David C. Pratt Cancer Center at St. John's Mercy

Jay W Carlson
Ph: 800-821-7532

Springfield

St. John's Regional Health Center

Jay W Carlson
Ph: 800-821-7532

Montana
Billings

Billings Clinic Cancer Center - 801 N 29th Street

Benjamin Thomas Marchello
Ph: 800-648-6274

Nebraska
Omaha

Fred and Pamela Buffett Cancer Center

Andrew O Wahl
Ph: 800-999-5465

New Jersey
Brick

Ocean Medical Center at Meridian Health

Douglas A Miller
Ph: 732-206-8384

Morristown

Carol G. Simon Cancer Center at Morristown Memorial Hospital

Yana P Goldberg
Ph: 973-971-5900

Mount Holly

Virtua Fox Chase Health Cancer Program at Virtua Memorial Hospital Burlington County

Lemuel S. Ariaratnam
Ph: 888-847-8823

Neptune

Jersey Shore Cancer Center at Jersey Shore University Medical Center

Douglas A Miller
Ph: 732-206-8384

Pennington

Capital Health Medical Center-Hopewell

Shirnett Karean Williamson
Ph: 800-255-3440

Red Bank

Booker Cancer Center at Riverview Medical Center

Douglas A Miller
Ph: 732-206-8384

Voorhees

Fox Chase Virtua Health Cancer Program at Virtua West Jersey

Lemuel S. Ariaratnam
Ph: 888-847-8823

New Mexico
Albuquerque

University of New Mexico Cancer Center

Thomas M Schroeder
Ph: 505-272-6972

New York
Bay Shore

Southside Hospital

Beatrice F Bloom
Ph: 516-562-3467

New Hyde Park

Long Island Jewish Medical Center

Beatrice F Bloom
Ph: 516-562-3467

Monter Cancer Center of the North Shore-LIJ Health System

Beatrice F Bloom
Ph: 516-562-3467

Stony Brook

Stony Brook University Cancer Center

Tamara Esther Weiss
Ph: 800-862-2215

North Carolina
Chapel Hill

Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill

Ellen L Jones
Ph: 877-668-0683
Email: cancerclinicaltrials@med.unc.edu

Charlotte

Presbyterian Cancer Center at Presbyterian Hospital

Justin P Favaro
Ph: 704-384-5369

Supply

South Atlantic Radiation Oncology, LLC

Michael A Papagikos
Ph: 910-251-1839

Wilmington

Coastal Carolina Radiation Oncology Center

Michael A Papagikos
Ph: 910-251-1839

North Dakota
Bismarck

Medcenter One Hospital Cancer Care Center

Preston D. Steen
Ph: 701-234-6161

Grand Forks

Altru Cancer Center at Altru Hospital

Grant R Seeger
Ph: 701-780-6520

Ohio
Akron

McDowell Cancer Center at Akron General Medical Center

Mitchell Lee Fromm
Ph: 330-344-6348

Summa Center for Cancer Care at Akron City Hospital

Charles A Kunos
Ph: 330-375-6101

Barberton

Barberton Citizens Hospital

Charles A Kunos
Ph: 330-375-6101

Chardon

Geauga Regional Hospital

Rodney J Ellis
Ph: 800-641-2422

Cleveland

Case Comprehensive Cancer Center

Tracy Sherertz
Ph: 800-641-2422

Medina

Summa Health Center at Lake Medina

Charles A Kunos
Ph: 330-375-6101

Mentor

Lake/University Ireland Cancer Center

Rodney J Ellis
Ph: 800-641-2422

Middleburg Heights

Southwest General Health Center

Rodney J Ellis
Ph: 800-641-2422

Orange Village

UHHS Chagrin Highlands Medical Center

Rodney J Ellis
Ph: 800-641-2422

Portsmouth

Southern Ohio Medical Center Cancer Center

J. Philip Kuebler
Ph: 800-446-5532

Ravenna

Robinson Radiation Oncology

Mitchell Lee Fromm
Ph: 330-344-6348

Westlake

UHHS Westlake Medical Center

Rodney J Ellis
Ph: 800-641-2422

Oklahoma
Oklahoma City

Stephenson Cancer Center at the University of Oklahoma

Terence S. Herman
Ph: 405-271-4272
Email: julie-traylor@ouhsc.edu

Pennsylvania
Danville

Geisinger Cancer Institute at Geisinger Health

Thomas J Gergel
Ph: 570-271-5251

Paoli

Cancer Center of Paoli Memorial Hospital

Albert S DeNittis
Ph: 866-225-5654

State College

Mount Nittany Medical Center

Jerome Derdel
Ph: 814-231-7813
Email: smoyer@mountnittany.org

West Reading

McGlinn Family Regional Cancer Center at Reading Hospital and Medical Center

Albert Yuen
Ph: 610-988-9323

Wynnewood

Lankenau Cancer Center at Lankenau Hospital

Albert S DeNittis
Ph: 866-225-5654

South Carolina
Charleston

Hollings Cancer Center at Medical University of South Carolina

Samuel L Cooper
Ph: 843-792-9321

Greenwood

Self Regional Cancer Center at Self Regional Medical Center

Samuel L Cooper
Ph: 843-792-9321

South Dakota
Rapid City

Rapid City Regional Hospital

Michael J Swartz
Ph: 605-716-3982
Email: research@rcrh.org

Sioux Falls

Sanford Cancer Center at Sanford USD Medical Center

Preston D. Steen
Ph: 701-234-6161

Texas
Dallas

Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas

Kevin V Albuquerque
Ph: 214-648-7097

San Antonio

University of Texas Health Science Center at San Antonio

Tony Y. Eng
Ph: 210-450-3800
Email: CTO@uthscsa.edu

Utah
Logan

Logan Regional Hospital

R. Jeffrey Lee
Ph: 801-507-3950

Murray

Jon and Karen Huntsman Cancer Center at Intermountain Medical Center

R. Jeffrey Lee
Ph: 801-507-3950

Saint George

Dixie Regional Medical Center - East Campus

R. Jeffrey Lee
Ph: 801-507-3950

Salt Lake City

LDS Hospital

R. Jeffrey Lee
Ph: 801-507-3950

Utah Cancer Specialists at UCS Cancer Center

R. Jeffrey Lee
Ph: 801-507-3950

Virginia
Richmond

Virginia Commonwealth University Massey Cancer Center

Emma C Fields
Ph: 804-628-1939

Washington
Federal Way

St. Francis Hospital

John A Keech
Ph: 907-458-5380

Seattle

CCOP - Virginia Mason Research Center

Huong T. Pham
Ph: 206-342-6954
Email: vmmc.cancer_clinical_research@VirginiaMason.org

West Virginia
Huntington

Edwards Comprehensive Cancer Center at Cabell Huntington Hospital

Maria-Rosalia B. Tria Tirona
Ph: 304-399-6617

Wheeling

Schiffler Cancer Center at Wheeling Hospital

Jon David Pollock
Ph: 304-243-6442

Wisconsin
Green Bay

Vince Lombardi Cancer Clinic - Green Bay at Aurora BayCare Medical Center

Mitchell H. Pincus
Ph: 800-252-2990

West Allis

Aurora Women's Pavilion of West Allis Memorial Hospital

Mitchell H. Pincus
Ph: 800-252-2990

Canada

British Columbia
Kelowna

British Columbia Cancer Agency - Centre for the Southern Interior

Francois Bachand
Ph: 250-712-3900

Victoria

British Columbia Cancer Agency - Vancouver Island Centre

Caroline L Holloway
Ph: 604-877-6010

Ontario
Hamilton

Margaret and Charles Juravinski Cancer Centre

Iwa Kong
Ph: 905-387-9495

London

London Regional Cancer Program at London Health Sciences Centre

Brian P Yaremko
Ph: 519-685-8600

Windsor

Windsor Regional Cancer Centre at Windsor Regional Hospital

Kenneth M Schneider
Ph: 519-253-5253

Saskatchewan
Regina

Allan Blair Cancer Centre at Pasqua Hospital

Evgeny Sadikov
Ph: 306-766-2213

Saskatoon

Saskatoon Cancer Centre at the University of Saskatchewan

Vijayananda Kundapur
Ph: 306-655-2914

Hong Kong

Chai Wan

Pamela Youde Nethersole Eastern Hospital

Amy T Chang
Ph: 888-823-5923
Email: ctsucontact@westat.com

Israel

Tel Hashomer

Chaim Sheba Medical Center

Richard J Lawrence
Ph: 972 3 530-5943

Republic of Singapore

Singapore

Cancer Institute at National University Hospital

Ihsiung J Tang
Ph: 888-823-5923
Email: ctsucontact@westat.com

Link to the current ClinicalTrials.gov record.
NLM Identifier NCT01672892
ClinicalTrials.gov processed this data on May 21, 2015

Note: Information about this trial is from the ClinicalTrials.gov database. The versions designated for health professionals and patients contain the same text. Minor changes may be made to the ClinicalTrials.gov record to standardize the names of study sponsors, sites, and contacts. Cancer.gov only lists sites that are recruiting patients for active trials, whereas ClinicalTrials.gov lists all sites for all trials. Questions and comments regarding the presented information should be directed to ClinicalTrials.gov.